author-photo

S. Meerwein

University of California, San Diego

12

Papers

415

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

2018 The Lancet
Show All
- Source
- Cite
- Save
Citations (183)
SAT0255 Patient reported outcomes of upadacitinib: results from biologic inadequate responders (SELECT BEYOND PHASE III TRIAL)

2018 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (2)
SAT0219 Upadacitinib in patients with active rheumatoid arthritis and inadequate response or intolerance to biological dmards: a phase 3 randomized, placebo-controlled, double-blind study of a selective jak1 inhibitor

2018 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (0)
A Randomized Phase 2b Study of ABT-494, a Selective JAK1 Inhibitor in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate.

2016 Arthritis & Rheumatism
Show All
- Source
- Cite
- Save
Citations (76)
Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate

2016 Rheumatology
Show All
- Source
- Cite
- Save
Citations (11)
OP0223 Safety and Efficacy of ABT-494, A Novel Selective JAK1 Inhibitor, in Patients with Active Rheumatoid Arthritis with An Inadequate Response To Methotrexate

2016 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (0)
AB0406 Effect of Adalimumab and Impact of Disease Activity and Functional Impairment on Work Instability in Patients with Rheumatoid Arthritis

2014 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (0)